International Day of Forests

March 21, 2018

By Steven King, PhD, EVP, Sustainable Supply, Ethnobotanical Research & IP March 21st is International Day of Forests, and it is hard to think of…

Read More

The Critical Role of Livestock in Ending World Hunger and Poverty

December 7, 2017

By Rustom Masalawala, Senior VP, International Markets Part of Jaguar’s staff contribution series In 2013, the World Bank estimated that there were 1.35 billion people…

Read More

Intestinal Lymphoma in Horses

November 28, 2017

By Siobhan McAuliffe, MVB, DACVIM, Foal Medicine Specialist Other than melanomas, cancer in horses is rare. Amongst those that can be seen are lymphomas and…

Read More

Our Commitment to Social Responsibility & Sustainability

November 22, 2017

By Kevin Bohnert, Senior Manager, Global Supply Chain Part of Jaguar’s staff contribution series Jaguar Health is committed to the principle of the triple bottom…

Read More

The Golden Retriever Lifetime Study

November 21, 2017

By Michael K. Guy, DVM, MS, PhD, Vice President and Clinical Veterinarian In my last position, I was the Director of the Golden Retriever Lifetime…

Read More

Our Chubby Cat – Living with Feline Diabetes

November 15, 2017

By Niki Waldron, Head of Formulation Part of Jaguar’s staff contribution series Diabetes is a chronic disease that occurs when the pancreas can’t make insulin…

Read More

Fluid Therapy & Dehydration in Calves with Diarrhea

November 14, 2017

By Andre Teixeira, DVM, PhD, Veterinary Affairs Director, Jaguar Health Despite ongoing efforts to control neonatal diarrhea, it remains a major concern in the U.S….

Read More

Pet Cancer Awareness

November 8, 2017

By Michael K. Guy, DVM, MS, PhD, Vice President and Clinical Veterinarian, Jaguar Health For many reasons, our dogs and cats are living longer than…

Read More

MYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Important Safety Information about MYTESI®
MYTESI® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI®.

If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

Click to Read Full Prescribing Information